CJC-1295

Also: CJC-1295 with DAC, CJC-1295 DAC, CJC-1295 no DAC, Modified GRF (1-29), Mod GRF 1-29, DAC:GRF

Research PeptideLimitedPrimarily preclinical and early pharmacology characterization (in vitro and animal models, with limited early human pharmacokinetic reports). Not an approved drug; handled as a research-use-only material. Human evidence is limited and requires careful interpretation.

This profile summarizes research context only. It is not medical advice and does not describe how to use this compound in humans or animals — no dosing, administration, or protocols. Learn more

This entry is a draft pending editorial and source verification. It is excluded from search indexing until reviewed.

CJC-1295 is a synthetic peptide discussed in the research literature as a long-acting analog of growth hormone-releasing hormone (GHRH), derived from a modified GHRH(1-29) sequence. It is described as a reference compound for studying GHRH-receptor signaling and the growth hormone (GH) axis, with its characterization drawn largely from in vitro work and early pharmacology and animal models. Terminology varies between sources: "CJC-1295" may refer to a version carrying a Drug Affinity Complex (DAC) or a version without DAC, which differ in reported properties and warrant source verification. Available evidence is limited and requires careful interpretation due to study design and translation limitations.

Mechanism as described in the literature

CJC-1295 is described in the research literature as a synthetic analog of growth hormone-releasing hormone (GHRH), based on a modified fragment of the GHRH(1-29) sequence. Amino-acid substitutions are reported to increase resistance to enzymatic degradation, and the "DAC" (Drug Affinity Complex) variant additionally carries a chemical group reported to bind serum albumin, which has been investigated as a way to extend circulating half-life.

Mechanistically, GHRH analogs are characterized in vitro and in animal models as agonists at the pituitary GHRH receptor, where they are reported to influence pulsatile secretion of growth hormone and, downstream, insulin-like growth factor 1 (IGF-1). These descriptions are mechanistic and preclinical in nature; human data are limited, and physiological or health outcomes should not be inferred from receptor-level activity alone.

Research areas

GHRH receptor pharmacology and the growth hormone axis (mechanistic)
Pulsatile GH and IGF-1 secretion dynamics in preclinical models
Peptide half-life extension chemistry (albumin-binding DAC modification)
Comparative pharmacology of GHRH analogs (DAC vs non-DAC variants)
Analytical identity, sequence, and purity characterization for documentation

Documentation notes

References

References for this entry are pending editorial verification. We do not publish citations we have not confirmed.

Frequently asked questions

What is CJC-1295?+

It is a synthetic peptide discussed in the research literature as a long-acting analog of growth hormone-releasing hormone (GHRH). It appears as a reference compound in laboratory and preclinical research contexts only and is not an approved therapeutic.

What is the difference between CJC-1295 'with DAC' and 'without DAC'?+

Sources describe a Drug Affinity Complex (DAC) version designed to bind serum albumin and a non-DAC version; the two are reported to differ in circulating half-life and are sometimes conflated under the same name. Because terminology varies, the specific identity should be confirmed against primary sources before drawing any conclusion.

Is CJC-1295 proven safe or effective?+

No. It is not an approved drug and is handled as a research-use-only material. Claims of safety or efficacy are not supported, and the existing evidence is limited and largely preclinical, requiring careful interpretation.